Moderna Wins EU Contract for RSV Vaccine, Up to 24M Doses
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna secured a European Commission contract to supply its RSV vaccine, mRESVIA, to six EU countries—Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal—for up to 24 million doses over four years. The deal expands the commercial footprint of its respiratory vaccine portfolio, which already includes COVID-19 and combination flu/COVID shots authorized in Europe. This follows a string of positive regulatory and clinical milestones, including unanimous FDA panel support for its flu vaccine and strong Q1 revenue. The ready-to-use prefilled syringe format could ease adoption. The contract adds a new, multi-year revenue stream at a time when the company is navigating significant net losses from litigation charges.
At the time of this announcement, MRNA was trading at $74.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3B. The 52-week trading range was $22.28 to $85.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.